Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022
First quarter (January-March 2022) · Operating profit/loss totaled SEK -4,741,051 (-2,404,551). · Loss for the period totaled SEK -4,754,615 (-2,404,489). · Cash flow from operating activities totaled SEK -5,333,226 (-3,481,034). · Earnings per share before dilution totaled SEK -0.24 (-0.20) Earnings per share after dilution amounted to SEK -0.24 (-0.20). Key events during the first quarter · Elicera Therapeutics boosted IP protection for ELC-100 through the acquisition of patents from Immunicum. · Elicera Therapeutics secured SEK 5 million in grant financing